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Abstract:  
In the United States, about a quarter of the estimated 1.1 million people living with human 
immunodeficiency virus (HIV) are not aware of their HIV status. HIV tests in communities with outreach 
settings can be an effective strategy to identify people with unidentified HIV infection. The spread of 
innovative rapid tests represents an additional opportunity in the field of HIV prevention. HIV rapid tests 
represent an excellent diagnostic tool to reach the rural or poor population where accessibility to test is 
limited or populations with high-risk infection. Cost-effectiveness point of view, this service always has the 
potential for early diagnosis by affecting lower hospital spending, preventing clinically aggravated cases 
with decreased CD4 and acquired immunodeficiency. The study analyses the characteristics of rapid tests 
by evaluating what can be used in Europe and Italy from case studies. The sensitivity, specificity and project 
needs are the main factors of choice in testing projects 
Keywords: Rapid Test, HIV, AIDS, Community based Service 
Introduction 
More than 1.1 million people in the United States are infected by HIV, and the CDC estimates that one out 
of six does not know it (Kidder et al. 2008; Coates et al. 2008). These uninformed people cause 54-70% of 
the 56,300 new infections each year (CDC, 2005). 75% of HIV + people will change risky behaviors when 
they learn their status (Kalichman et al., 2005). It is estimated that in Italy, like other European countries, 
there is a significant proportion of people with HIV infection (about a third) who are unaware of being HIV-
positive. Moreover, it has been shown that approximately 30% of HIV infection diagnoses are made in 
people who already reached an advanced stage of disease (CD4 <200 / MMC lymphocytes and / or 
pathologies indicative of AIDS) and nearly 60% of AIDS diagnoses is made in people with late recognition 
of HIV infection. This phenomenon leads to several negative consequences. First, the person with late-
diagnosed HIV does not have the opportunity to start the antiretroviral therapy in best times and, on the one 
hand, has a higher risk of reaching full-blown disease and, on the other hand, a reduced probability of a full 
immunological recovery once pharmacological treatment has started. The lack of awareness of the infection 
condition may favour the further spread of the contagion. It has indeed been shown that people with HIV 
infection reduce, in part or completely, the behaviours at risk of transmitting the infection once informed of 
their status. In addition, there is evidence of the effectiveness of prevention interventions on the contagion 
spread addressed to people with known HIV infection. The antiretroviral therapy, reducing the viral load, 
can also help limit the spread of contagion. Indeed, a person aware of his / her serological status being 
ineffective therapy has a very limited risk of transmitting the infection to others. Finally, pregnant women 
aware of having HIV infection can access maternal-fetal prophylaxis programmes that drastically reduce 
transmission of the virus to the unborn child. In view of the high number of seropositive people still unaware 
of their serological status, it is considered strategic, priority and urgent to recognize the importance and to 
activate early detection actions that allow early contact and diagnosis of these people. Studies have shown 
that HIV counseling offer and tests on HIV in communities with outreach settings can be an effective 
strategy to identify people with unidentified HIV infection (CDC 2007). Effective HIV test mechanisms are 
already in use in the world, including some countries in Africa (Steen et al., 2007). The spread of innovative 
rapid tests, giving results in less than 30 minutes and over 99% in both sensitivity and specificity, represents 
a further opportunity in the field of HIV prevention (Branson et al., 2007; Doyle, 2005). 
MSMs, drug addicts, and sex workers are the most vulnerable ethnicities, and all the studies conducted in 
the most industrialized countries focused their research on them, with the difference that in the USA studies 
were also aimed at African- Americans and Hispanics, given their wide presence in that country and their 
high percentages of infections (Biancone et al., 2018). The evidence of the literature regarding the benefits 
of using a rapid test, even in terms of cost-effectiveness, is growing (Bert et al. 2018). Some articles 
highlight the organizational characteristics, the cost and the effectiveness of some projects carried out 
towards high-risk populations in Italy (Tradori et al., 2017). 
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The data of the “Research project for the identification and the experimentation of intervention models apt to 
improve membership in HIV screening test" (funded by the Ministry of Health, coordinated by the National 
Institute of Health and realized with the contribution of the Associations that are part of the AIDS Fighting 
Consultation) highlight a situation of extreme heterogeneity of the HIV test offer today in Italy. 
Medical devices and in vitro diagnosis in Italy and Europe 
The placing on the market and putting into service in the Italian and European territory of medical devices 
bearing the CE marking is permitted.  This marking demonstrates compliance, respectively, with Legislative 
Decree 46/97 (implementation of Directive 93/42 / EEC). With the EC declaration of conformity, the 
manufacturer guarantees and declares that the products in question satisfy various provisions. The 
manufacturer prepares the required technical documentation. The manufacturer or the representative shall 
keep said documentation, including the declaration of conformity, a provision of national authorities for 
control purposes for at least five years from the date of manufacture of the last product. The documentation 
includes, in particular, a general description of the product, including the expected variations and the uses 
for which it is intended, the design schemes and manufacturing methods, the diagrams of the parts, the parts, 
the circuits, etc., the description and the explanations. necessary for understanding the schemes the results of 
the risk analysis and a list of the rules laid down, applied in full or in part, and a description of the solutions 
adopted to meet the essential requirements of this decree where the rules laid down have not been fully 
applied. in the case of products placed on the market in a sterile package, the description of the methods 
used and the validation report, the results of the design calculations, the checks carried out, etc. If a device is 
to be connected to one or more other devices for operate according to the intended purpose, the conformity 
of the first device with the essential requirements must be demonstrated in connection with at least one of 
the devices to which it is to be connected, which possesses the characteristics indicated by the manufacturer, 
the solutions adopted, the preclinical evaluation, the clinical evaluation and labeling and instructions for use. 
The clinical evaluation and related documentation are actively updated with data from post-sales 
surveillance. Where you do not consider Post-sale clinical follow-up within the surveillance plan is 
necessary after-sales applied to the device, this conclusion must be duly justified and documented. Not all 
the devices highlighted in the analysis meet the legal requirements and can be considered for use in Italy and 
in Europe. 
Methodology 
The study group conducted a systematic review of the literature by identifying publications through TUTTO 
bibliographic database. This includes: Scopus (Elsevier), MEDLINE / PudMed, Science Citation Index 
(Web of Science), ProQuest Psychology Journals, ScienceDirect Journals (Elsevier), ProQuest Sociology, 
Sociological Abstracts, PMC PubMed Central), SpringerLink, Social Services Abstracts, Taylor & Francis 
Online - Journals, Informa - Taylor & Francis (CrossRef), Directory of Open Access Journals (DOAJ), 
JSTOR Archival Journals, Wiley Online Library, (BMJ Publishing Group), Wolters Kluwer - Ovid - 
Lippincott Williams & Wilkins (CrossRef), Lippincott Williams & Wilkins Journals (Wolters Kluwer 
Health). The words “community-based HIV test” were used both individually and in common for research, 
and only articles in English and Italian were selected, although the database identified only articles in 
English. The bibliography included revised periodicals, including articles and conferences. The research 
considered all the identifiable sources of the period between 2008 and 2017. The criteria identified in the 
research of literature were checked on the title and on the abstract. The initial results were 53,321, from a 
first analysis 31 articles with administration projects of the community-based test were selected. 
Subsequently, all magazines that did not have a result of the effectiveness of the HIV rapid testing project 
were excluded, highlighting those with the presence and the identification of the HIV TEST used, reducing 
the analysis to 12 articles. The characteristics relating to the product were conducted through market 
research and the request for estimates associated with the qualitative analysis of the observable 
characteristics conducted in the year 2017. The aim is to identify the effective cost of the various HIV rapid 
tests based starting from the best practices identified in the literature and the possibility to check the 
typologies and characteristics to be evaluated for prevention and diagnosis activities in Italy and Europe. 
Discussion 
Analysis of literature and projects of HIV early diagnosis 
For the purposes of the analysis, the following articles have been taken into consideration, of which a brief 
description is given for the sake of clarity. 
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1)Implementation of Rapid Testing Programs in Community and Outreach Settings: Perspectives from Staff 
at Eight Community-Based Organizations in Seven U.S. Cities (published in 2008 and realized between 
2004 and 2006 in the cities of Boston, Chicago, Detroit, Kansas City [Missouri], Los Angeles, San 
Francisco, Washington). 
Research based on the effectiveness of HIV rapid tests methods on the basis of MTU run by eight CBO. 
This research was conducted by surveying CBO staff. Among the positive aspects, there is the effectiveness 
of promotional activity and the ability to reach individuals at high risk of contracting the disease. Among the 
negative aspects, there are the high costs involved in staff training but above all the purchase and 
maintenance costs associated with MTU, which are also accompanied by logistical difficulties. Another 
challenging difficulty lies in the fact that many people, once having done the test within an MTU, are 
unapproachable if HIV-positive because contact information is often false (Clark, 2008). 
2)Cost-Effectiveness of Finding New HIV Diagnoses Using Rapid HIV Testing in Community-Based 
Organizations (published in 2008 and realized between April 2004 and March 2006 in the cities of Kansas 
City [Missouri], Detroit). 
Cost-effectiveness ratio in evaluating HIV tests in CBO. It turned out that in Kansas, where the clinic was 
also present, the HIV tests “conducted on the streets” brought higher costs. These costs have been found by 
dividing the total cost of the programme for the number of people who have been notified of new HIV 
diagnoses. Indeed, it has been found out that people who knew they had had sex at risk and therefore they 
contracted the disease, prefer to go to the clinic rather than to use mobile testing units (MTU) so that the 
percentage of people at risk is only 0.7% versus 2.2% of the clinic. In Detroit, however, where there are no 
clinics, costs are cheaper as MTU is a unique opportunity to conduct the test. Therefore, in Kansas, it is not 
advisable to continue investing in mobile units to conduct HIV rapid tests, while in Detroit it is and it is 
expected that, while continuing to invest, the results (costs-benefits) will only improve (Shrestha, 2008). 
3)Rapid HIV Testing in Transgender Communities by Community-Based Organizations in Three Cities 
(published in 2008 and realized from January 2005 to December 2006 in the cities of Miami Beach (Florida), 
San Francisco, New York City). 
Study of the demographic and behavioural characteristics of transgender people (TG) recruited through 
outreach strategies. It has emerged that among these people, the risk of contracting HIV is higher because of 
their behaviour and lifestyles (especially at-risk sex and injection of hormones and silicone). Therefore, 
efforts should be increased to develop new awareness and prevention strategies for these people, for 
example by encouraging them to do the test at least every year (Schulden, 2008). 
 
4)Number and timing of antenatal HIV testing: Evidence from a community-based study in Northern 
Vietnam (published in 2011 and realized in Quang Ninh, a province north of Vietnam, between April and 
September 2007 among women who had given birth within 6 months from January, 1 to June 30, 2007). The 
study aims to document the absorption of HIV test among pregnant women in order to analyze the timing 
and repetitions of the test. The results of this study will contribute to the formation of the national guidelines 
for the PMTCT programme. 90.3% (1000 out of 1108) of the interviewed women were tested during 
pregnancy, 38.2% of them once and 52.1% twice or more times (usually women living in a semi-urban area). 
However, 80% did the second test after 36 weeks of gestation (it is advisable before. Otherwise the effect of 
the PMTCT service offered is reduced). Among those tested, 94.7% had received schooling and had at least 
one level of secondary education, while in terms of employment, the most of them were housewives or 
unemployed. Among those not tested, it was found out that for the majority it was the second child's 
pregnancy, that they were farmers or had a seasonal job, lived in a remote rural area, had low income, had 
poor schooling and education. It can be said that the risk of contracting the virus during pregnancy, in 
Vietnam, is low (also due to the fact that Vietnamese women have stable sex life); this is why the use of 
repeating the HIV test has been questioned because of the costs for both the health system and the people, 
considering that most of the population lives in poverty; so that for women who were negative at the first 
test, proper counselling is provided during the rest of the pregnancy, without the need to repeat the test 
(Hạnh, 2011). 
5)High acceptance of home-based HIV counseling and testing in an urban community setting in Uganda 
(published in 2011 and realized between January and June 2009 on the population of Rubaga, part of the city 
of Kampala, Uganda). This study analyzed the level of acceptance of Home-Based HIV Counselling and 
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Testing (HBHCT) (i.e., HIV rapid test did door to door), in a country, like Uganda, where coverage and 
access to tests remain low. HBHCT has proven to have a 69% acceptance level and therefore to increase 
HIV test absorption and to improve access. Indeed, 39% of participants had never been tested. In this study, 
it was found out that men were more likely to accept the test than women, but this probably may be due to 
the fact that the latter, especially in reproductive age, are more in touch with the healthcare system and have 
therefore more access, just think of the PMTCT programme, for example. These HBHCT strategies have 
great advantages of improving early identification of HIV-positive individuals, also increasing awareness of 
care treatment and limiting their sexual at-risk behaviour; but the success of such strategies could be 
hampered by the lack of qualified healthcare professionals and by high operating costs in view of limited 
resources (Sekandi, 2011). 
6)Risk factors for HIV and STI diagnosis in a community-based HIV/STI testing and counseling site for men 
having sex with men (MSM) in a large German city in 2011-2012 (published in 2015 and realized between 
2011 and 2012). This article explains the risk factors of contracting HIV and other STI among MSM in 
Hamburg, leaning on Heine & Fiete, a local community part of CB-VCT. Here, HIV, HBV, HCV, syphilis, 
gonorrhoea and Chlamydia tests were conducted and offered in free and anonymous form; the choice on 
which tests to conduct on participants was based on pre-test counseling. Out of 1476 men tested, 1413 were 
tested for HIV, followed by syphilis (1380). 295 men were tested at least twice by Hein & Fiete in the last 
two years, 69% had a high school diploma or higher education degree, 87% were gay, 53% were single, and 
MSM had on average from 6 to 11 different sex partners over the past 12 months, unprotected anal sex (UAI) 
was reported by 61% of clients as the main reason for evidence. General data show how this CB-VCT site in 
Hamburg has reached MSM at high risk of contracting HIV and bacterial STI, and although a cost-
effectiveness analysis has not been conducted, considering the high affluence and low overall costs, this test 
is used to reduce percentages of HIV and STI infections that are not diagnosed in a profitable way compared 
to traditional treatment settings. So far, there have not been cost problems since they were covered by public 
funds, but in the future, when the nucleic acid amplification test for Gonorrhoea and Chlamydia will be 
included, these costs will increase, and an option to contain them and minimize them could be the use of 
combined tests. However, this approach is only feasible in large cities where the respective gay communities 
are also significant; alternative approaches will also be needed to reach MSM living in rural areas, MSM 
that is less connected to gay communities and MSM who are less willing to self-identify as homosexuals 
(Marcus, 2015). 
7)The prevalence and correlates of receiving confirmatory HIV test results among newly diagnosed HIV-
positive individuals at a community-based testing center (published in 2012 and realized between March 
2008 and February 2011 in New York City). This research studies the correlations between people who 
conduct HIV test and those who even make confirmation tests if they are positive. A study has shown that if 
every person over 15 years had a voluntary annual test in combination with immediate anti-retroviral 
therapy after diagnosis, the incidence and mortality of HIV would be reduced to less than 1 case per 1000 
people from 2016 and the HIV prevalence would be reduced to less than 1% within 50 years. This research 
was done using both conventional test (ELISA) and rapid test. The HIV seropositive people opting for 
traditional HIV ELISA test are significantly more than those who opt for rapid test, as people who know 
they have contracted an infection prefer to go to the appropriate locations and practice ELISA. It emerged 
that 65% of people who were positive in the tests (both rapid and ELISA) then validated this result with a 
confirmation test, lower rate compared to those reported in other studies, ranging from 75 to 89%. It also 
emerged that the greatest probability to receive the confirmation test came from uninsured, homeless people 
and non-US citizens since these people will be able to access the assistance of organizations offering AIDS 
service and benefit from public advantages, like becoming beneficiaries of the New York State AIDS Drug 
Assistance Program. Here also the results are not consistent with other studies, indeed a piece of research on 
a sample of teenage girls at a clinic in Cleveland, Ohio, stated that those with private insurance were most 
likely to return for the confirmation test, while the homeless were those with a lesser likelihood. The 
explanations for these differences are: 1. the different composition and methodology of the sample; 2. the 
fact that the latter study was conducted between 1992 and 1995, i.e. before the introduction of antiretroviral 
drugs, so there were fewer “incentives” for the poorest people to return for the confirmation test. In addition, 
individuals tested off-site within a mobile unit are less likely to return for confirmatory tests, this time the 
result is consistent with previous studies. The main reason behind the latter one is that it depends on the 
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motivations: indeed, who goes to a GMHC center is mentally ready to conduct the test and to accept all 
possible consequences, but who goes to mobile units may have done so deciding on the moment and 
therefore is not ready for the possibility of a positive diagnosis. A possible solution to this problem may be 
to give those who conduct the test off-site the possibility to receive the results of the confirmatory tests in 
the same area where the test is being conducted. Finally, there are some promising developments that can 
help reduce the gap between test and treatment; indeed processes that give a positive HIV diagnosis, that do 
not require confirmation tests are being studied, but the link to treatment could start immediately instead of 1 
week later (Feldman, 2012). 
8)Evaluation of Pharmacy-Based HIV Testing in a High-Risk New York City Community (published in 2015 
and realized between June 2010 and August 2011 in the neighbourhoods of East Harlem and Central Harlem 
in New York City). This study evaluated the delivery of HIV test based on pharmacy clients in 
neighbourhoods with high HIV infection rates. Research has shown that this strategy is feasible because it 
reaches at-risk populations by providing health counselling and vaccination services to all customers, 
consistently with US objectives. The cost-effectiveness link that these innovative strategies give, deserves 
greater attention because it facilitates access to treatments which would extend life, preserve health, prevent 
HIV transmission, and help reduce racial / ethnic disparities in health. The next step should be to include in 
research those factors that help overcome all those individual and structural barriers, such as information 
programmes directed to all pharmacy clients on HIV tests. The statistical results were: 332 participants, of 
which 99 were HIV positive and were excluded from this analysis, so the analytical sample is based on 233 
clients of ESAP pharmacies. Most of the participants were males, born in the United States, unmarried, with 
an education going from high school up, about 20% were homeless. Among the at-risk behaviours: in the 30 
days before the test, 55.3% reported that they did not use the condom and 10.3% had sex with people of the 
same sex; 88.4% dealt in their life with drug with 55.8% with non-injecting drugs. Most reported having 
been tested at least once in their life (most during the previous year) and having health insurance. It was also 
found out that great part of the people who went to the pharmacy, were sexually active and with multiple 
partners, that they had not recently been tested (<12 months) and had been taking drugs for the last 3 months; 
i.e. all those categories that can be catalogued as at higher risk of infection (Amesty, 2015). 
9)Early Identification of HIV: Empirical Support for Jail-Based Screening (published in 2012 and realized 
between September 2008 and March 2011 in the cities of: Atlanta-GA, Chester-PA, Chicago-IL, Cleveland-
OH, Columbia-SC, New Haven-CT, New York-NY, Philadelphia-PA, Providence-RI, Springfield-
Massachusetts). 
This article deals with the largest HIV prevention programme carried out in jails. Jails can be effective sites 
for diagnoses of new infections and to begin implementing routine care, as most of these people use drugs 
and abuse alcohol, behaviours that contribute to the transmission of the virus. One of the objectives of this 
study was to evaluate the connection with the HIV support community among those who then went out of 
jail. The results were: 210267 are the prisoners (not just the inmates) who were tested, and 1312 (0.62%) 
results were positive, 822 of the diagnoses were new (although this last screening is not uniform from site to 
site, indeed in some, the probability of new diagnoses was significantly higher). Among prisoners, 43% (329) 
were diagnosed within a correctional structure, of whom 62% (36) were male, 67% (39) black and 12% (7) 
Hispanic. Clients who accepted the test had an average jail stay of 75 days. Of the new diagnosed, as regards 
at-risk behaviours, 11% said they were using drugs in their lives, 19% had homosexual or bisexual 
orientation, 25% had sexual intercourse with other men in last 30 days. The results of this project suggest 
that HIV test conducted in jails is feasible and can lead to new infection diagnoses and these are essentially 
diagnosed at the initial stage of the disease. Unfortunately, the jails that adhere to such programmes are in 
the minority. Another advantage lies in the fact that projections within jails lead to a disease detection that 
would have been impossible to diagnose in other settings (De Voux, 2012). 
10)Biomarker-Based HIV Incidence in a Community Sample of Men Who Have Sex with Men in Paris, 
France (published in 2012 and realized in 2009 in Paris). 
This is the first community-based study to estimate the HIV incidence among MSM in France. Data are not 
positive. Indeed we have high levels of HIV transmission (3.8% of people per year) and a low rate of 
antiretroviral therapy absorption, as unfortunately happens for all high-income countries. The present study 
clearly shows that MSM frequenting gay places in Paris have a very high risk of contracting the disease 
(almost 18% have HIV and have high-risk behaviours). However, the acceptance rate was 58%, in line with 
International Journal of Management Sciences and Business Research, Mar-2018 ISSN (2226-8235) Vol-7, Issue 3 
http://www.ijmsbr.com  Page 110 
the percentage of gay places in the rest of Europe and Australia. The statistical results were: 1578 men 
invited to participate, 917 (58%) accepted and 886 (56%) completed the questionnaire and provided a blood 
sample. Of the 886 MSM participating, 157 (18%) were positive, of whom 31 (20%) were unaware of their 
infection; 94% reported having been tested earlier and of these, 63% within the previous year. In addition, 
antiretroviral drugs were reported in 9 out of the 12 samples (75%) positive to EIA-RI, among the men who 
reported being aware of their infection (Le Vu, 2012). 
11)Home-Based HIV Testing for Men Who Have Sex with Men in China: A Novel Community-Based 
Partnership to Complement Government Programs (published in 2014 and realized in 2012 on MSM in 
Beijing). In China, the HIV test is available either through VCT clinics or through public hospitals. This 
article evaluated the feasibility of Home-Based HIV Self-Testing, because of the many barriers that still 
exist and are hard to overcome, such as the lack of time to visit clinics and the concern of discrimination 
from clinic staff (be it perceived or real). Results: 220 participants, 80% with homosexual orientation, 33 
(15%) found positive with self-test and then linked to a local CDC (all of them were confirmed with 
Western blot); furthermore, 65% stated that they felt less stigmatized in conducting the test at a CBO and 
even more comfortable receiving certain services compared to traditional clinics; finally, only 49% had 
already been tested, although 87% of participants said they knew where to go to conduct the test. Self-test 
can offer a valid alternative to tests conducted in conventional places, having the benefit of reduced 
concerns about confidentiality, greater flexibility in execution, elimination of long waiting periods for 
screening results, as well as overcoming the barriers already cited. However, there are also concerns, such as: 
knowing exactly how to conduct exactly the test, difficulties in providing an adequate pre- and post-
counseling service and knowing how to connect HIV-positive patients with care. HIV tests conducted with 
this approach can help increase coverage and consequently improve the quality of life of positive MSM. The 
next step is to expand this approach even in rural areas, well aware of the logistical problems in providing 
test kits in these places; indeed the participants in this study were internet users (the advertisement of this 
programme could only be found on the CCAVG website) relatively young and educated and therefore the 
results cannot be generalized to all MSM (Tao, 2014). 
12)Community-Based HIV-1 Early Diagnosis and Risk Behavior Analysis of Men Having Sex with Men in 
Hong Kong (published in 2015 and realized between March 2010 and April 2011 between MSM of Hong 
Kong). In this study, it is shown how early HIV infection can be diagnosed by combining a DBS (dried 
blood spot) method with a rapid test, always in local community settings. This is because the rapid test is 
able to detect only the presence of the HIV specific antibody, while the traditional test gives more accurate 
results but has unaffordable costs for an NGO (Non-Governmental Organization) and therefore this setting 
was thought, that offered at the same time cost accessibility and higher sensitivity of the results (it can detect 
HIV-1 in the proviral DNA at a lower level). Results: 474 valid participants, only 24.5% claimed to have 
regular partners, 57.6% said they had up to 3 partners and 29.1% 4 up in the 3 months before the test; only 
46.4% (220/474) regularly used condoms; 19 individuals were found HIV positive (4.01%), 13 of whom 
were found to be positive for both analyses, 3 only for rapid test but not for DBS (due to insufficient DNA 
and low proviral copies), 4 out of 19 positive claimed to have been found negative to tests conducted about 6 
months earlier, suggesting they had been at risk and contracted the virus during this time period, other three 
individuals of the 19 were found to be positive only to DBS. Another alarming datum is the high rate of 
refusal (48%) and the objective for future studies is to improve this datum, given that Hong Kong is 
experiencing, for the second time in its history, a major HIV epidemic among MSM, with a large expansion 
even among heterosexuals (Liang, 2015). 
This article does not consider cases where rapid testing is associated with hospital facilities (Bert et al., 
2016); but only considers cases where the test is used for projects outside healthcare facilities and hospitals. 
Test type 
Table 1 shows the test types used by every project, each of which is indicated by technical characteristics, 
i.e., test type, directions for use and response time, on which biological fluid it is possible to conduct them 
and, on this basis, sensitivity and specificity. Sensitivity is defined as the ability of the test to identify sick 
subjects while specificity is the ability of the test to identify healthy subjects as negative. 
Almost all projects employed rapid tests with response time ranging from 10 to 20 minutes. The sensitivity 
of the analysed tests ranges from a minimum of 83.3 to a maximum of 99.9, considering that the sample can 
be analysed on blood, plasma, and oral fluid. With regard to the test specificity, there is a variation between 
International Journal of Management Sciences and Business Research, Mar-2018 ISSN (2226-8235) Vol-7, Issue 3 
http://www.ijmsbr.com  Page 111 
99.7 and 100 for groups at low risk. Most tests give the possibility to have a result by analysing whole blood 
or plasma, while only a few also give the possibility to conduct an analysis of the oral fluid. 
Table 1 Characteristics of employed tests 
Reference 
article 
Test type 
Directions 
for use and 
response 
time 
Test practicable 
on Sensitivity Specificity 
1 
Rapid and conventional test. Rapid 
test: OraQuick Rapid HIV-1 
Antibody Test or OraQuick 
Advance Rapid HIV-1/2 Antibody 
Test (OraSure Technologies, 
Bethlehem, Pennsylvania) on 
samples of whole blood or oral fluid 
Finds HIV 1 
- 2 
antibodies 
in response 
in 20 
minutes 
Whole blood, oral 
fluid, plasma 
Whole blood 99.6 
(98.5-99.9), oral 
fluid 99.3 (98.4-
99.7), plasma 99.6 
(98.5-99.9) 
Whole blood 100 
(99.7-100), oral 
fluid 99.8 (99.6-
99.9), plasma 99.9 
(99.6-99.9) 
2 
Rapid and conventional test. Rapid 
test: OraQuick Rapid HIV-1 
Antibody Test or OraQuick 
Advance Rapid HIV-1/2 Antibody 
Test (OraSure Technologies, 
Bethlehem, Pennsylvania) on 
samples of whole blood or oral 
fluid. Those who had a positive test 
result were asked to conduct a 
confirmative test by Western Blot. 
Finds HIV 1 
- 2 
antibodies 
with 
response in 
20 minutes 
Whole blood, oral 
fluid, plasma 
Whole blood 99.6 
(98.5-99.9), oral 
fluid 99.3 (98.4-
99.7), plasma 99.6 
(98.5-99.9) 
Whole blood 100 
(99.7-100), oral 
fluid 99.8 (99.6-
99.9), plasma 99.9 
(99.6-99.9) 
3 
HIV rapid test: OraQuick Advance 
Rapid HIV-1/2 Antibody Tests 
(OraSure Technologies, Bethlehem, 
Pennsylvania) on samples of oral 
mucosa or sample of whole blood 
taken from the finger. Those who 
had a positive test result were asked 
to conduct a confirmative test by 
Western Blot. 
Finds HIV 1 
– 2 
antibodies 
in response 
in 20 
minutes 
Whole blood, oral 
fluid, plasma 
Whole blood 99.6 
(98.5-99.9), oral 
fluid 99.3 (98.4-
99.7), plasma 99.6 
(98.5-99.9) 
 
4 / 
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5 
Rapid test door to door. The HIV-
1/2 dosage (Abbott Laboratories, 
Illinois, United States of America) 
was used for the selection, for the 
confirmative test the HIV-1/2 
STAT-PACK was used (Chembio 
Diagnostic System Inc, New York, 
USA), as tie-breaker the Uni-Gold 
test was used (Trinity Biotech, 
Wicklow, Ireland). You are positive 
to the test if the Uni-gold gives a 
positive result.  
Clearview 
HIV 1/2 
STAT-PAK 
(antibodies 
HIV 1 - 2 
results in 15 
minutes), 
Uni-Gold 
Recombigen 
HIV-1/2 
(antibodies 
HIV 1 - 2, 
resulting in 
10 minutes) 
Clearview HIV 1/2 
STAT-PAK (test 
finger stick on 
capillary blood or 
whole venous 
blood), Uni-Gold 
Recombigen HIV-
1/2 (whole blood, 
blood serum / 
plasma) 
Clearview HIV 1/2 
STAT-PAK test 
finger stick on 
capillary blood or 
whole venous blood 
99.7 (98.9-100); 
Uni-Gold 
Recombigen HIV-
1/2 whole blood, 
blood serum / 
plasma100 (99.5-
100.0) 
Clearview HIV 1/2 
STAT-PAK test 
finger stick on 
capillary blood or 
whole venous blood 
99.9 (99.6-100.0),  
Uni-Gold 
Recombigen HIV-
1/2 whole blood, 
blood serum / 
plasma 99.7 (99.0-
100) 
6 
Abbott  Architect HIV Ag/Ab 
Combo, reactive samples were 
confirmed by Mickrogen, 
recomLine HIV-1 & HIV-2 IgG 
testing.  
Antibodies 
against 
HIV-1 and 
HIV-2 
detects an 
HIV-1 
antigen, 
results in 20 
minutes 
finger stick on 
whole blood 
Finger stick on 
whole blood 99.9 
(99.4-100) 
Finger stick on 
whole blood: 
subjects at low risk 
100 (99.5-100), 
subjects at high risk 
99.7 (98.9-100) 
International Journal of Management Sciences and Business Research, Mar-2018 ISSN (2226-8235) Vol-7, Issue 3 
http://www.ijmsbr.com  Page 113 
7 
Traditional HIV test (ELISA) and 
rapid test for rapid tests conducted 
at place the finger stick ones are 
used (Uni-Gold Recombigen; 
Trinity Biotech USA, Jamestown, 
NY), for tests conducted off-site or 
in the mobile unit HIV oral tests are 
used (OraQuick Rapid HIV-1 
Antibody Test, OraSure 
Technologies, Bethlehem, PA). If 
these rapid tests are positive, the 
first ones are confirmed with 
enzymatic immunodosage (HIV-1/2 
Antibody Plus EIA; Quest 
Diagnostics, San Jose, CA) or with 
Western blot (HIV-1 Western Blot; 
Unilab, Tarzana, CA), the second 
ones with confirmative oral tests 
(OraSure HIV-1 Western blot, 
OraSure Technologies, Bethlehem, 
PA). 
Uni-Gold 
Recombigen 
HIV-1/2 
(HIV 1 – 2 
antibodies, 
resulting in 
10 minutes), 
OraQuick 
ADVANCE 
Rapid HIV-
1/2 
Antibody 
Test (finds 
HIV 1 – 2 
antibodies 
with 
response in 
20 minutes) 
Uni-Gold 
Recombigen HIV-
1/2 (whole blood, 
blood serum / 
plasma), finds HIV 
1 - 2 antibodies 
with response in 20 
minutes, OraQuick 
ADVANCE Rapid 
HIV-1/2 Antibody 
Test (whole blood, 
oral fluid, plasma) 
 Uni-Gold 
Recombigen HIV-
1/2 whole blood, 
blood serum / 
plasma100 (99.5-
100.0), OraQuick 
ADVANCE Rapid 
HIV-1/2 Antibody 
Test whole blood 
99.6 (98.5-99.9), 
oral fluid 99.3 (98.4-
99.7), plasma 99.6 
(98.5-99.9) 
Uni-Gold 
Recombigen HIV-
1/2 whole blood, 
blood serum / 
plasma 99.7 (99.0-
100), OraQuick 
ADVANCE Rapid 
HIV-1/2 Antibody 
Test whole blood 
100 (99.7-100), oral 
fluid 99.8 (99.6-
99.9), plasma 99.9 
(99.6-99.9) 
8 
Rapid test. Salivary test OraQuick 
ADVANCE HIV-1/2 Antibody 
Test. If you are found positive, 
blood is collected through 
phlebotomy and sent to a laboratory 
for confirmation test through 
Western Blot, linking them to care. 
Finds HIV 1 
– 2 
antibodies 
with 
response in 
20 minutes 
Whole blood, oral 
fluid, plasma 
Whole blood 99.6 
(98.5-99.9), oral 
fluid 99.3 (98.4-
99.7), plasma 99.6 
(98.5-99.9) 
Whole blood 100 
(99.7-100), oral 
fluid 99.8 (99.6-
99.9), plasma 99.9 
(99.6-99.9) 
9 / 
 
   
10 
Genscreen ultra HIV Ag-Ab was 
used; Biorad and the blood sample 
was taken from the fingertip. 
Positive samples were confirmed by 
Western blot and then by EIA-RI. 
Finds HIV 1 
– 2 
antibodies 
in response 
in 20 
minutes 
Finger stick on 
whole blood, 
plasma  
Whole blood or 
plasma 90 
(96.7 – 83.3) 
Whole blood or 
plasma 99,5 
(99,20 – 99,9) 
11 
For Home-Based HIV Self-Testing 
project, the rapid test kit is used 
(Human Immuno-deficiency Virus 
HIV ½ Antibody Rapid Test, 
ABON Biopharm Co. Ltd, 
Hangzhou, China). Those who were 
positive were linked to a local CDC 
for a second screening test (Alere 
Determine HIV-1/2, Abbott 
Laboratories, Illinois, USA. In case 
of double positivity, confirmation 
test with Western blot (HIV Blot 
Version 2.2, MP Biomedicals Asia 
Pacific Pte. Ltd, Singapore). 
 
   
International Journal of Management Sciences and Business Research, Mar-2018 ISSN (2226-8235) Vol-7, Issue 3 
http://www.ijmsbr.com  Page 114 
12 
Rapid test integrated with DBS 
(dried blood spot) to give more 
precision. Determine HIV 1/2 test 
was used (Abbott Laboratory, North 
Chicago, Illinois, USA). 
Antibodies 
against 
HIV-1 and 
HIV-2 
detects an 
HIV-1 
antigen, 
results in 20 
minutes 
finger stick on 
whole blood 
Finger stick on 
whole blood 99.9 
(99.4-100) 
Finger stick on 
whole blood: 
subjects at low risk 
100 (99.5-100), 
subjects at high risk 
99.7 (98.9-100) 
source: own production 
In Table 2 we can observe the market price where found, the presence of CE marking, the expiry date and 
the required degree Celsius for preservation. Suppliers, in the absence of CE marking, did not provide the 
price list. Prices vary considerably depending on the test type, minimum 8.90 € maximum 20 € each; the 
preservation period varies from 3 to 24 months, the minimum and maximum preservation range are also 
very variable. Many products did not obtain CE marking so at the moment they cannot be used in the 
European context. 
Table 2 Product characteristics of rapid tests 
Test type   EEC marking 
Expiry date (months)/preservation 
temperature °C 
OraQuick Advance Rapid HIV-1/2 Antibody Test (OraSure 
Technologies, Bethlehem, Pennsylvania)  10 € X 
30 months/ from 2° to 30° 
HIV-1/2 (Abbott Laboratories, Illinois, United States of America)   
There is no CE 
mark 
18 months/from 15° to 30° 
HIV-1/2 STAT-PACK (Chembio Diagnostic System Inc, New York, 
USA)   
There is no CE 
mark 
24 months/from 8° to 20° 
Uni-Gold test (Trinity Biotech, Wicklow, Ireland)   
There is no CE 
mark 
12 months/from 2° to 27° 
Abbott  Architect HIV Ag/Ab Combo 9 € x 3 months/from 2° to 8° 
OraSure HIV-1 Western blot, OraSure Technologies, Bethlehem, PA   x 24 months/from 1° to 30° 
Genscreen ultra HIV Ag-Ab, Biorad    
There is no CE 
mark 
18 months/from 2° to 30° 
HIV ½ Antibody Rapid Test, ABON Biopharm Co. Ltd, Hangzhou, 
China   
There is no CE 
mark 
24 months/from 22 to 30° 
Determine HIV 1/2 test (Abbott Laboratory, North Chicago, Illinois, 
USA)   
THere is no CE 
mark 
18 months/from 2° to 30° 
HIV 1/2 GENIE FAST BIO-RAD 20 € x 18 months/from 2° to 30° 
Alere Determine HIV-1/2, Abbott Laboratories, Illinois, USA 8,9 x 18 months/from 2° to 30° 
source: own production 
Conclusion 
The three parameters for the choice of the most effective test should be sensitivity, specificity, and price but, 
unfortunately, it is very often difficult to compare the characteristics of sensitivity and specificity of the 
different test types as they may have different performances according to the context in which they are used. 
Moreover, the accuracy of the results depends not only on the test characteristics but also on the capacity of 
the executor and on the quality and quantity of the sample taken (Ippolito, 2015). Test sensitivity indicators 
have considerable variations to be evaluated when choosing the test to be used; for the purposes of cost-
effectiveness analysis, it is important in this case to evaluate whether in the diagnostic course an ELISA 
check-up test and CD4 count are provided for the therapy to be implemented, otherwise, where the social or 
infrastructure situation does not allow the access to a full diagnosis it is important to choose the rapid test 
with greater sensitivity indicator (Hạnh, 2011; Sekandi, 2011). The typology of test analysed by literature is 
suitable for quick evaluation on the basis of the administration setting, on mobile stations or outside setting 
it is necessary to use rapid tests on oral fluid, while where the available setting is stable and equipped to 
ensure a low risk of infection with staff properly trained for testing activity, it is possible to conduct the test 
on whole blood or plasma. Specificity indicators do not show significant variations. The test cost must 
consider the variables of sensitivity, specificity and setting considered first. During the planning of diagnosis 
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courses, it is important to highlight test preservation periods, projects with long-term low turnout could lead 
to inefficiencies in the choice of short expiry products (3 months), but almost all the tests taken into 
consideration starting from literature have a medium long-term expiry 18-30 months. Except for a test 
typology (Abbott Architect HIV Ag / Ab Combo), all others have variable preservation temperatures that do 
not impact on the use of tests even in differentiated settings. As highlighted by literature, HIV rapid tests are 
cost-effective only in cases where the population at high risk for behaviour can be tested for behaviour and 
where the structuring of the test service is not guaranteed by proper infrastructure. HIV rapid tests have been 
identified as a valid diagnostic tool for the prevention of HIV and AIDS (National AIDS Commission, 2011, 
Ministry of Health, 2015). Piedmont Region is one of the first to identify the test as a tool to be taken into 
consideration according to the Regional Plan also in order to integrate the services already provided by the 
regional healthcare system (Seremi, 2016). HIV rapid tests answer to the need to identify any positivity in 
populations with a risk behaviour where there is no awareness of the serological state and there is no a 
culture of early diagnosis among the population. In Italy, most tests used in community based research 
projects cannot be used because of CE marking absence, limiting the possibility and choice. The article is 
based on projects identified in literature with significant results in terms of relapse; surely there will be 
better evidence in the future with projects based on fourth-generation HIV rapid testing and on self-
diagnosis projects (Kelvin et al., 2016; Maksut et al., 2016)  
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